Academic Journals Database
Disseminating quality controlled scientific knowledge

TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN

ADD TO MY LIST
 
Author(s): Ramzi Jeddi | Hèla Ghédira | Ramzi Ben Amor | Yosr Ben Abdennebi | Kacem Karima | Zarrouk Mohamed | Hend Ben Neji | Lamia Aissaoui | Raihane Ben Lakhal | Naouel Ben Salah | Samia Menif | Zaher Belhadjali | Hela Ben Abid | Emna Gouider | Raouf Hafsia | Ali Saad | Pierre Fenaux | Balkis Meddeb

Journal: Mediterranean Journal of Hematology and Infectious Diseases
ISSN 2035-3006

Volume: 3;
Issue: 1;
Start page: e2011033;
Date: 2011;
Original page

Keywords: Leukemia

ABSTRACT
In Tunisia, the ATRA era began in 1998 with the use, consecutively, of two regimens combining ATRA and an anthracycline with cytarabine (APL93), and without cytarabine (LPA99). From 2004, 51 patients with confirmed APL either by t(15;17) or PML/RARA were treated according to the PETHEMA LPA 99 trial. Forty three patients achieved CR (86%). The remaining seven patients had early death (one died before treatment onset): four caused by differentiation syndrome (DS) and three died from central nervous system hemorrhage. Multivariate analysis revealed that female gender (P=0.045), baseline WBC> 10 G/L ( P=0.041) and serum creatinine > 1.4mg/dl ( P=0.021) were predictive of mortality during induction. DS was observed in 16 patients (32%) after a median onset time of 15 days from treatment onset (range, 2–29). Body mass index ≥ 30 (P=0.01) was the only independent predictor of DS. Occurrence of hypertensive peaks significantly predicted occurrence of DS (P=0.011) and was significantly associated with high BMI (p=0.003). With a median follow-up of 50 months, 5 year cumulative incidence of relapse, event free and overall survival were 4.7%, 74% and 78%, respectively.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?